Revolutionary ExoPTEN Therapy: FDA’s New Hope for Spinal Injuries
NurExone Biologic Inc., a leading biotechnology company, has recently achieved a significant milestone in the development of treatments for acute spinal cord injuries. The U.S. Food and Drug Administration (FDA) has granted Orphan-Drug Designation (ODD) to the company’s innovative ExoPTEN therapy. This designation is crucial for conditions like acute spinal cord injury, where effective treatments […]